ArticleBioconjugate chemistry2013
Nanoparticle PET/CT imaging of natriuretic peptide clearance receptor in prostate cancer.
Article in Bioconjugate chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 51 citations in OpenAlex.
- Molecular targets and the emerging role of copper radionuclides in prostate cancer theranostics.EJNMMI research · 2025Review
- The role and clinical value of natriuretic peptide receptor family in malignant tumor.Cell death discovery · 2025Review
- Nanoradiopharmaceuticals: Design Principles, Radiolabeling Strategies, and Biomedicine Applications.Pharmaceutics · 2025Review
- Exploring innovative strides in radiolabeled nanoparticle progress for multimodality cancer imaging and theranostic applications.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology.European journal of medical research · 2024Review
- Functional Diversity in Radiolabeled Nanoceramics and Related Biomaterials for the Multimodal Imaging of Tumors.ACS bio & med chem Au · 2023Review
- Antibacterial coatings on orthopedic implants.Materials today. Bio · 2023Review
- A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer.Frontiers in oncology · 2023Review
- Recent Advances in Gadolinium Based Contrast Agents for Bioimaging Applications.Nanomaterials (Basel, Switzerland) · 2021Review
- Assessment of ultrasmall nanocluster for early and accurate detection of atherosclerosis using positron emission tomography/computed tomography.Nanomedicine : nanotechnology, biology, and medicine · 2021Article
- Natriuretic Peptides Regulate Prostate Cells Inflammatory Behavior: Potential Novel Anticancer Agents for Prostate Cancer.Biomolecules · 2021Article
- CC Chemokine Receptor 5 Targeted Nanoparticles Imaging the Progression and Regression of Atherosclerosis Using Positron Emission Tomography/Computed Tomography.Molecular pharmaceutics · 2021Article
- New Frontiers in Molecular Imaging Using Peptide-Based Radiopharmaceuticals for Prostate Cancer.Frontiers in chemistry · 2020Review
- Assessment of Targeted Nanoparticle Assemblies for Atherosclerosis Imaging with Positron Emission Tomography and Potential for Clinical Translation.ACS applied materials & interfaces · 2019Article
- Applications of nanoparticles in biomedical imaging.Nanoscale · 2019Review
- Natriuretic Peptides: The Case of Prostate Cancer.Molecules (Basel, Switzerland) · 2017Review
- Molecular Imaging in Nanotechnology and Theranostics.Molecular imaging and biology · 2017Review
- Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.International journal of molecular sciences · 2017Review
- Semiconducting polymer nanoparticles as photoacoustic molecular imaging probes.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- Nanoparticles and radiotracers: advances toward radionanomedicine.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Atrial natriuretic peptide has been recently discovered to have anticancer effects via interaction with cell surface natriuretic peptide receptor A (NPRA) and natriuretic peptide clearance receptor (NPRC). In a preclinical model, NPRA expression has been identified during tumor angiogenesis and may serve as a potential prognostic marker and target for prostate cancer (PCa) therapy. However, the presence of NPRC receptor in the PCa model has not yet been assessed. Furthermore, there is still no report using nanoparticle for PCa positron emission tomography (PET) imaging. Herein, an amphiphilic comb-like nanoparticle was synthesized with controlled properties through modular construction containing C-atrial natriuretic factor (CANF) for NPRC receptor targeting and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator for high specific activity Cu-64 radiolabeling. The pharmacokinetics of (64)Cu-CANF-Comb exhibited tuned biodistribution and optimized in vivo profile in contrast to the nontargeted (64)Cu-Comb nanoparticle. PET imaging with (64)Cu-CANF-Comb in CWR22 PCa tumor model showed high blood pool retention, low renal clearance, enhanced tumor uptake, and decreased hepatic burden relative to the nontargeted (64)Cu-Comb. Immunohistochemistry staining confirmed the presence of NPRC receptor in tumor tissue. Competitive PET receptor blocking study demonstrated the targeting specificity of (64)Cu-CANF-Comb to NPRC receptor in vivo. These results establish a new nanoagent for prostate cancer PET imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.